Midostaurin, also known as PKC-412, PKC-412A and CGP 41251; is a synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.
PKC Inhibitors Related Products:
GSK690693; Staurosporine; Valrubicin; ML-7 HCl; Go6976; TAS-301; Fasudil; Fasudil (HA-1077) HCl; HA-1100 Hydroxyfasudil; Enzastaurin